Long-Term Glycemic Variability and Risk of Cardiovascular Events in
                    Type 2 Diabetes: A Meta-Analysis

Ting Wang; Xin Zhang; Jian Liu

doi:10.1055/a-1730-5029

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2022; 54(02): 84-93
DOI: 10.1055/a-1730-5029

Endocrine Care

Long-Term Glycemic Variability and Risk of Cardiovascular Events in Type 2 Diabetes: A Meta-Analysis

Ting Wang‡

¹Department of Medical Administration, The First Hospital of Hunan University of Chinese Medicine, Changsha, China

,

Xin Zhang‡

²Department of Gastroenterology, The Fourth Hospital of Changsha, Changsha, China

,

Jian Liu

³Department of Emergency, The First Hospital of Hunan University of Chinese Medicine, Changsha, China

› Institutsangaben

Abstract

Long-term glycemic fluctuation has been associated with cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). However, the findings are inconsistent. We performed a meta-analysis to summarize the association between parameters of long-term glycemic variability and risk of cardiovascular events in T2DM patients. Medline, Embase, and Web of Science databases were searched for longitudinal follow-up studies comparing the incidence of cardiovascular events in T2DM patients with higher or lower long-term glycemic variability. A random-effect model incorporating the potential heterogeneity among the included studies was used to pool the results. Twelve follow-up studies with 146 653 T2DM patients were included. The mean follow-up duration was 4.9 years. Pooled results showed that compared to those with the lowest glycemic variability, patients with the highest glycemic variability had significantly increased risk of cardiovascular events, as evidenced by the standard deviation of glycated hemoglobin [HbA1c-SD: relative risk (RR)=1.44, 95% confidence interval (CI): 1.23 to 1.69, p<0.001; I²=70%], HbA1c coefficient of variation (HbA1c-CV: RR=1.46, 95% CI: 1.19 to 1.79. p<0.001; I²=83%), standard deviation of fasting plasma glucose (FPG-SD: RR=1.33, 95% CI: 1.07 to 1.65, p=0.009; I²=0%), and FPG coefficient of variation (FPG-CV: RR=1.29, 95% CI: 1.01 to 1.64, p=0.04; I²=47%). In conclusion, increased long-term glycemic variability may be an independent risk factor for cardiovascular events in T2DM patients.

Key words

glycemic variability - type 2 diabetes mellitus - cardiovascular events - meta-analysis

Volltext

Referenzen

References
1 Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011; 378: 169-181
2 Pandey A, Chawla S, Guchhait P. Type-2 diabetes: Current understanding and future perspectives. IUBMB Life 2015; 67: 506-513
3 [Anonymous] 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. . Diabetes Care 2020; 43: S111-S134
4 [Anonymous] Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care 2020; 43: S66-S76
5 Buse JB, Wexler DJ, Tsapas A. et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 2020; 43: 487-493
6 Haas AV, McDonnell ME. Pathogenesis of cardiovascular disease in diabetes. Endocrinol Metab Clin North Am 2018; 47: 51-63
7 Bergman M, Abdul-Ghani M, DeFronzo RA. et al. Review of methods for detecting glycemic disorders. Diabetes Res Clin Pract 2020; 165: 108233
8 Sun B, Luo Z, Zhou J. Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. Cardiovasc Diabetol 2021; 20: 9
9 Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010; 12: 288-298
10 Gorst C, Kwok CS, Aslam S. et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care 2015; 38: 2354-2369
11 Kovatchev B. Glycemic variability: risk factors, assessment, and control. J Diabetes Sci Technol 2019; 13: 627-635
12 Papachristoforou E, Lambadiari V, Maratou E. et al. Association of glycemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications. J Diabetes Res 2020; 7489795
13 Luk AO, Ma RC, Lau ES. et al. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong diabetes registry. Diabetes Metab Res Rev 2013; 29: 384-390
14 Hirakawa Y, Arima H, Zoungas S. et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care 2014; 37: 2359-2365
15 Takao T, Matsuyama Y, Suka M, Yanagisawa H. et al. The combined effect of visit-to-visit variability in HbA1c and systolic blood pressure on the incidence of cardiovascular events in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2015; 3: e000129
16 Lee MY, Hsiao PJ, Huang YT. et al. Greater HbA1c variability is associated with increased cardiovascular events in type 2 diabetes patients with preserved renal function, but not in moderate to advanced chronic kidney disease. PLoS One 2017; 12: e0178319
17 Cardoso CRL, Leite NC, Moram CBM. et al. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol 2018; 17: 33
18 Critchley JA, Carey IM, Harris T. et al. Variability in glycated hemoglobin and risk of poor outcomes among people with type 2 diabetes in a large primary care cohort study. Diabetes Care 2019; 42: 2237-2246
19 Sun B, He F, Gao Y. et al. Prognostic impact of visit-to-visit glycemic variability on the risks of major adverse cardiovascular outcomes and hypoglycemia in patients with different glycemic control and type 2 diabetes. Endocrine 2019; 64: 536-543
20 Kaze AD, Santhanam P, Erqou S. et al. Long-term variability of glycemic markers and risk of all-cause mortality in type 2 diabetes: the Look AHEAD study. BMJ Open Diabetes Res Care 2020; 8: e001753
21 Li S, Nemeth I, Donnelly L. et al. Visit-to-visit HbA1c variability is associated with cardiovascular disease and microvascular complications in patients with newly diagnosed type 2 diabetes. Diabetes Care 2020; 43: 426-432
22 Scott ES, Januszewski AS, O’Connell R. et al. Long-term glycemic variability and vascular complications in type 2 diabetes: post hoc analysis of the FIELD study. J Clin Endocrinol Metab 2020; 105 dgaa361
23 Sato M, Inaishi J, Saisho Y. et al. Association of visit-to-visit glycemic variability with risk of cardiovascular diseases in high-risk Japanese patients with type 2 diabetes: a subanalysis of the EMPATHY trial. J Diabetes Investig 2021; 12: 2190-2196
24 Shen Y, Zhou J, Shi L. et al. Association between visit-to-visit HbA1c variability and the risk of cardiovascular disease in patients with type 2 diabetes. Diabetes Obes Metab 2021; 23: 125-135
25 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012
26 Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration. 2011 www.cochranehandbook.org
27 Wells GA, Shea B, O’Connell D. et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2010 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
28 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
29 Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 2008; 37: 1148-1157
30 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
31 Wang A, Liu X, Xu J. et al. Visit-to-visit variability of fasting plasma glucose and the risk of cardiovascular disease and all-cause mortality in the general population. J Am Heart Assoc 2017; 6: e006757
32 Jang JY, Moon S, Cho S. et al. Visit-to-visit HbA1c and glucose variability and the risks of macrovascular and microvascular events in the general population. Sci Rep 2019; 9: 1374
33 Yu JH, Han K, Park S. et al. Effects of long-term glycemic variability on incident cardiovascular disease and mortality in subjects without diabetes: A nationwide population-based study. Medicine (Baltimore) 2019; 98: e16317
34 Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?. Int J Mol Sci 2014; 15: 18381-18406
35 Sun J, Xu Y, Dai Z. et al. Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin. Mol Cell Endocrinol 2009; 313: 64-69
36 Ren Y, Tao S, Zheng S. et al. Salvianolic acid B improves vascular endothelial function in diabetic rats with blood glucose fluctuations via suppression of endothelial cell apoptosis. Eur J Pharmacol 2016; 791: 308-315
37 Otowa-Suematsu N, Sakaguchi K, Komada H. et al. Comparison of the relationship between multiple parameters of glycemic variability and coronary plaque vulnerability assessed by virtual histology-intravascular ultrasound. J Diabetes Investig 2018; 9: 610-615
38 Zhang T, Su G, Mi SH. et al. Association between blood glucose variability and the characteristics of vulnerable plaque in elderly non-ST segment elevation acute coronary syndrome ppatients. Int Heart J 2019; 60: 569-576
39 Ito T, Nakasuka K, Fujita H. et al. Impact of glucose variability on coronary plaque vulnerability in patients with dysglycemia: A whole coronary analysis with multislice computed tomography. J Cardiol 2022; 79: 58-64